Skip to main content
. Author manuscript; available in PMC: 2022 Aug 1.
Published in final edited form as: Ann Surg Oncol. 2021 Jan 7;28(8):4615–4622. doi: 10.1245/s10434-020-09518-y

Fig. 3.

Fig. 3.

Recurrence free survival (RFS) by circulating tumor cell (CTC) status. (a) RFS in patients with peripheral blood CTC counts of < 3 per 7.5 mL and ≥ 3 per 7.5 mL; 18-month RFS rates, 62% and 31%, respectively (p=0.13). (b) RFS rates in patients with portal vein blood CTC counts of < 1 and ≥ 1 per 7.5 mL; 18-month RFS rates, 67% and 37%, respectively (p=0.29).